Breed & Life‑Stage Dosing Notes

Context checklist before finalising any dose or protocol.

Clinical Notes

Age & Life‑Stage

Puppy, Adult & Senior Considerations

Life‑stage frameworks divide dogs into puppy, young adult, mature adult, senior, and end‑of‑life, with care plans tailored to each stage.

Life stage Key pharmacology points
Puppy / Juvenile Immature hepatic and renal clearance; avoid long half‑life or narrow‑index drugs when safer alternatives exist and adjust dose intervals where needed.
Adult Standard mg/kg ranges usually apply, but lifestyle, body condition, and concurrent disease still modify risk.
Senior / Geriatric Reduced cardiac, renal, and hepatic reserve; many references suggest starting at 33–50% of usual dose or extending intervals for narrow‑index or nephrotoxic agents.

Breed & Size

Breed‑Linked Sensitivities

Certain breeds carry MDR1 or other mutations that increase sensitivity to specific drugs even at routine doses.

Breed examples Drug / class to use cautiously Notes
Collies, Australian Shepherds, related herding breeds Ivermectin and selected macrocyclic lactones Dogs with MDR1 mutation can show neurotoxicity at doses tolerated by other breeds; genetic testing or safer alternatives are recommended for high‑dose uses.
Giant breeds Growth‑plate‑affecting drugs, chronic steroids Rapid growth and joint loading mean long‑term steroid plans need extra caution and owner counselling around weight and exercise.
Toy / small breeds Concentrated oral liquids, insulin, potent sedatives Small absolute body weight magnifies dosing errors; use syringes with fine graduations and double check unit conversions.

Body Condition

Obesity & Under‑Conditioning

Obese dogs often need dosing based on lean or adjusted body weight for some drugs, particularly those with narrow therapeutic indices.

  • For lipophilic drugs, total body weight may overestimate the safe dose in very obese animals; check references for adjusted‑weight formulas.
  • Under‑conditioned or cachectic dogs can have reduced protein binding and altered distribution, so slow titration and closer monitoring are prudent.

Organ Function

Renal & Hepatic Reserve

Many references recommend reducing dose by about 25–50% or extending intervals when moderate to severe renal or hepatic impairment is present.

  • For renally cleared drugs, extending the interval can be safer than full‑dose frequent administration in dogs with CKD.
  • In hepatic insufficiency, guidelines frequently suggest starting hepatically cleared drugs at half the usual dose or with longer intervals where no safer option exists.